Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$84.13 -0.8%	$84.51	$57.52 ▼ $117.19	$32.99B	1.44	4.43 million shs	2.35 million shs
HAE Haemonetics	$74.46 -0.2%	$71.23	$55.30 ▼ $94.99	$3.58B	0.39	676,992 shs	665,704 shs
HQY HealthEquity	$97.67 +1.5%	$101.21	$65.01 ▼ $116.65	$8.45B	0.49	871,267 shs	940,815 shs
LNTH Lantheus	$74.41 -8.4%	$79.17	$69.51 ▼ $122.83	$5.15B	0.12	979,517 shs	4.16 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	-0.64%	+1.22%	+3.40%	+23.35%	-24.98%
HAE Haemonetics	-2.62%	-2.05%	+6.51%	+31.10%	-17.32%
HQY HealthEquity	-1.19%	-6.73%	-8.19%	+16.60%	+24.81%
LNTH Lantheus	-2.17%	-1.40%	+4.41%	-19.16%	-34.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXCM DexCom	4.783 of 5 stars	3.5	3.0	4.7	3.6	2.5	1.9
HAE Haemonetics	4.8862 of 5 stars	4.5	3.0	4.3	2.0	1.7	2.5
HQY HealthEquity	3.0088 of 5 stars	3.5	1.0	0.0	2.2	2.5	1.9
LNTH Lantheus	4.6257 of 5 stars	3.5	2.0	4.2	3.2	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.91	Moderate Buy	$99.60	18.39% Upside
HAE Haemonetics	3.00	Buy	$97.30	30.68% Upside
HQY HealthEquity	3.00	Buy	$118.55	21.37% Upside
LNTH Lantheus	3.00	Buy	$131.20	76.32% Upside

Current Analyst Ratings Breakdown

Latest HAE, DXCM, HQY, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	DXCM DexCom	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$95.00 ➝ $100.00
7/15/2025	DXCM DexCom	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$82.00 ➝ $89.00
7/11/2025	HAE Haemonetics	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$95.00
7/9/2025	HAE Haemonetics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$90.00
7/8/2025	HQY HealthEquity	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$115.00 ➝ $120.00
6/26/2025	HAE Haemonetics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/25/2025	HAE Haemonetics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/16/2025	DXCM DexCom	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$102.00
6/5/2025	HQY HealthEquity	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $125.00
6/5/2025	HQY HealthEquity	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$98.00 ➝ $115.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.03B	8.18	$2.22 per share	37.97	$5.38 per share	15.64
HAE Haemonetics	$1.36B	2.63	$7.00 per share	10.64	$16.34 per share	4.56
HQY HealthEquity	$1.24B	6.79	$4.28 per share	22.83	$24.40 per share	4.00
LNTH Lantheus	$1.53B	3.36	$6.35 per share	11.71	$15.65 per share	4.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.34	62.78	34.20	1.82	12.90%	30.05%	10.00%	7/30/2025 (Estimated)
HAE Haemonetics	$167.68M	$3.31	22.49	14.77	1.24	12.32%	26.37%	9.22%	8/14/2025 (Estimated)
HQY HealthEquity	$96.70M	$1.37	71.29	34.39	1.51	9.80%	11.01%	6.77%	9/2/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	21.14	11.79	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)

Latest HAE, DXCM, HQY, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	DXCM DexCom	$0.45	N/A	N/A	N/A	$1.13 billion	N/A
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
6/3/2025	Q1 2026	HQY HealthEquity	$0.81	$0.97	+$0.16	$0.61	$322.25 million	$330.80 million
5/8/2025	Q4 2025	HAE Haemonetics	$1.22	$1.24	+$0.02	$1.17	$329.38 million	$330.60 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/1/2025	Q1 2025	DXCM DexCom	$0.33	$0.32	-$0.01	$0.27	$1.02 billion	$1.04 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
HAE Haemonetics	N/A	N/A	N/A	N/A	N/A
HQY HealthEquity	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.55	1.50	1.32
HAE Haemonetics	1.12	1.62	0.99
HQY HealthEquity	0.50	4.06	4.06
LNTH Lantheus	0.49	5.74	5.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
HAE Haemonetics	99.67%
HQY HealthEquity	99.55%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
HAE Haemonetics	1.84%
HQY HealthEquity	1.50%
LNTH Lantheus	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	10,300	392.11 million	390.85 million	Optionable
HAE Haemonetics	3,023	48.04 million	47.16 million	Optionable
HQY HealthEquity	3,120	86.48 million	85.18 million	Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable

HAE, DXCM, HQY, and LNTH Headlines

Recent News About These Companies

Why Lantheus (LNTH) Stock Is Down Today

2 hours ago | msn.com

Lantheus (NASDAQ:LNTH) Hits New 52-Week Low - Here's Why

July 16 at 10:59 AM | marketbeat.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by New York State Common Retirement Fund

July 16 at 4:33 AM | marketbeat.com

Rice Hall James & Associates LLC Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 14 at 6:39 AM | marketbeat.com

Genus Capital Management Inc. Buys Shares of 7,600 Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 12, 2025 | marketbeat.com

3,582 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by Concurrent Investment Advisors LLC

July 12, 2025 | marketbeat.com

Correct Capital Wealth Management Invests $644,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 10, 2025 | marketbeat.com

Bridges Investment Management Inc. Increases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 10, 2025 | marketbeat.com

Principal Financial Group Inc. Has $25.23 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 9, 2025 | marketbeat.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Buy" from Analysts

July 8, 2025 | marketbeat.com

1 Safe-and-Steady Stock on Our Watchlist and 2 to Keep Off Your Radar

July 7, 2025 | finance.yahoo.com

New York State Teachers Retirement System Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 5, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 3, 2025 | marketbeat.com

Lantheus’s Q1 Earnings Call: Our Top 5 Analyst Questions

July 2, 2025 | msn.com

Keybank National Association OH Has $56.30 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 2, 2025 | marketbeat.com

Lantheus Seems Worth The (Very Real) Risks

July 1, 2025 | seekingalpha.com

Peregrine Capital Management LLC Sells 5,148 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

June 30, 2025 | marketbeat.com

Riley Maintains ‘Buy’ Rating on Lantheus Holdings, Inc. (LNTH); Lowers PT

June 29, 2025 | insidermonkey.com

Lisanti Capital Growth LLC Acquires New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

June 29, 2025 | marketbeat.com

Lantheus Holdings Inc Analysis & Opinion (LNTH) - Investing.com

June 28, 2025 | investing.com

LNTH - Lantheus Holdings Inc Trailing Returns | Morningstar

June 26, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE, DXCM, HQY, and LNTH Company Descriptions

DexCom NASDAQ:DXCM

$84.13 -0.65 (-0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$84.19 +0.06 (+0.07%)

As of 07:16 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Haemonetics NYSE:HAE

$74.46 -0.17 (-0.22%)

Closing price 03:59 PM Eastern

Extended Trading

$74.44 -0.02 (-0.03%)

As of 05:44 PM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HealthEquity NASDAQ:HQY

$97.67 +1.49 (+1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$97.62 -0.05 (-0.05%)

As of 05:12 PM Eastern

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

Lantheus NASDAQ:LNTH

$74.41 -6.85 (-8.43%)

Closing price 04:00 PM Eastern

Extended Trading

$74.10 -0.30 (-0.41%)

As of 07:58 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time